Products
Brexpiprazole was approved in the United States in 2015 and in the EU and many countries in 2018 in film-coated tablet form (Rexulti).
Structure and properties
Brexpiprazole (C25H27N3O2S, Mr = 433.6 g/mol) is structurally closely related to aripiprazole (Abilify, generics).
Effects
Brexpiprazole (ATC N05AX16) has antipsychotic properties. The effects are due to partial agonism at serotonin-5-HT1A– and dopamine-D2 receptors as well as antagonism at serotonin-5-HT2A receptors. The half-life is long, approximately 90 hours.
Indications
For the treatment of schizophrenia in adult patients. Also used in some countries for the treatment of a depressive episode (major depression) in combination with antidepressants.
Dosage
According to the SmPC. Tablets are taken once daily, independent of meals. Treatment is started gradually.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Brexpiprazole is a substrate of CYP3A4 and CYP2D6 and corresponding interactions with CYP inhibitors and inducers are possible.
Adverse effects
The most common potential adverse effects include weight gain and akathisia (motor agitation).